Steroid premedication to protect lungs during breast cancer treatment
Treatments studied
Part of Cancer, Lungs & breathing, Skin clinical trials.
This trial tests whether a steroid called dexamethasone, given before T-DXd, can reduce the risk of a rare but serious lung side effect (interstitial lung disease) in people with advanced breast cancer. If it works, it may make treatment safer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- Your breast cancer has spread to other parts of the body (metastatic)
- You are going to start treatment with a targeted drug called trastuzumab deruxtecan (also known as T-DXd)
- You are in generally good physical shape (able to do light work or be fully active)
- Your blood counts, liver and kidney tests are within acceptable limits
- You do not have serious lung problems or diabetes that is not well controlled
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of a targeted drug (T-DXd) with brain radiation for women with breast cancer that has spread to the brain and is HER2-positive or HER2-low. The goal is to see if this approach is safe and works better than radiation alone.
This trial tests a steroid drug combined with standard hormone therapy to see if it can make the cancer respond again. It is for people with hormone receptor positive, HER2 negative breast cancer that has spread and stopped responding to previous hormone treatments.
This trial tests a new drug called Dato-DXd for people with a certain type of advanced breast cancer that has stopped responding to hormone therapy. The drug targets a protein on cancer cells to help stop the cancer from growing.
This study looks at how well Trastuzumab Deruxtecan (T-DXd) works in Chinese women with breast cancer that has spread. It is for people whose cancer is either HER2-positive or HER2-low and who have already had some treatment.
This study tests a drug called T-DXd (trastuzumab deruxtecan) for people with advanced breast cancer that has very low levels of HER2 (a protein that helps cancer grow) and that is also hormone receptor positive. The goal is to see if this drug can help shrink or slow the cancer.
This trial tests a new way of giving the targeted drug T-DXd—directly into the fluid around your spine (intrathecal) or through a device under your scalp called an Ommaya reservoir. It's designed for people with HER2-positive breast cancer that has spread to the brain or the lining of the brain/spinal cord.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.